Search for: "MEDICIS PHARMACEUTICAL CORPORATION"
Results 1 - 20
of 24
Sorted by Relevance
|
Sort by Date
9 May 2007, 5:10 pm
Medicis Pharmaceutical Corporation of Scottsdale, Arizona will pay $9.8 million to settle allegations that the company violated the False Claims Act by promoting the use of a topical skin preparation, Loprox, for use on children under the age of 10, without approval by the Food and Drug Administration (FDA). [read post]
11 May 2007, 4:00 am
Medicis Pharmaceutical Corporation of Scottsdale, Ariz., agreed to pay the United States $9.8 million to settle allegations that the company violated the False Claims Act with respect to claims submitted to Medicaid, according to a Department of Justice announcement earlier this week. [read post]
29 Jul 2010, 9:49 pm
By James DeGiulio -- Medicis Pharmaceuticals Settles Solodyn Litigation with Mylan Medicis Pharmaceuticals Corporation has reached settlement and license agreements with Mylan, Inc., thus resolving the patent litigation over Solodyn. [read post]
17 Oct 2008, 8:37 am
Plaintiffs file securities class action against Medicis Pharmaceutical Corporation. [read post]
22 Jun 2007, 6:21 am
As an example of the problem, we noted in an article published in the Corporate Crime Reporter on May 8, 2007, that Medicis Pharmaceutical Corporation of Scottsdale, Arizona had agreed to pay $9.8 million to settle allegations filed under the False Claims Act against the company. [read post]
5 Apr 2012, 7:42 am
Jonah Shacknai, chairman and chief executive of Medicis Pharmaceutical (MRX) got one of the latter kinds in 2011 — but it isn’t quite what it seems, which may be unsurprising given the company’s colorful approach to pay. [read post]
11 Aug 2011, 7:52 am
That’s what we found tacked on to the end of the 10-Q that Medicis Pharmaceutical (MRX) filed at a few minutes before 5 p.m. on Tuesday. [read post]
10 Feb 2012, 10:06 am
In addition, four of its current and former partners were sanctioned for violating PCAOB rules and standards.E&Y conducted audits of the financial statements of Medicis Pharmaceutical Corporation ("Medicis") for the periods ending December, 31, 2005, 2006 and 2007. [read post]
27 Jul 2011, 1:01 am
Highlights this week included: Corporate self-interest and strategic choices: Gilead licenses to Medicines Patent Pool (IP Watch) (KEI) Glybera (Alipogene tiparvovec) – EU: EMA continues to defer approval of first gene therapy application in Europe (Patent Docs) Cenestin (Synthetic conjugated estrogens) – US: CAFC: Prosecution history estoppel bars Duramed’s allegations of infringement under doctrine of equivalents: Duramed Pharmaceuticals, Inc. v. [read post]
16 Nov 2011, 2:27 am
This acne-fighting drug is manufactured for the drug company Medicis Pharmaceutical Corporation. [read post]
16 Oct 2010, 1:50 pm
The ‘355 patent is currently the subject of a litigation styled Medicis Pharmaceutical Corporation v. [read post]
14 Oct 2008, 10:44 pm
Medicis Pharmaceuticals: On October 3, 2008, plaintiffs’ lawyers filed a securities class action lawsuit in the District of Arizona against Medicis Pharmaceuticals, a specialty pharmaceutical company, and certain of its directors and officers. [read post]
17 Jan 2008, 10:00 pm
: (Against Monopoly),Structuring a decentralized world - Institute for Ethics and Emerging Technologies: The necessity of open biotechnology: (Patent Lens),A skeptical look at the Automated Content Access Protocol: (Ars Technica),5 practical things to incorporate in a corporate IP strategy: (IP ThinkTank), Legal models for online content enforcement: (OpenContentLawyer),Germany, Chinese copies and misdirected ‘strategy':… [read post]
17 Sep 2010, 9:15 am
MinSURG Corporation et al. [read post]
27 Mar 2009, 8:00 am
; no skulduggery involved in pharma enquiry submission switch says EPO (IPKat) (IAM) Superior Court of Justice reviews date from which TRIPS came into effect - Patent term cutbacks in Brazil and pharmaceutical pipelines (IP Think Tank) (IP Think Tank) (IP tango) Harmonisation in Denmark: Patents covering pharmaceutical compositions may now be designated as basic patents (The SPC Blog) General GSK reports on corporate responsibility activities 2008/9 including… [read post]
3 Jan 2013, 2:21 pm
Tigert involved a fairly straightforward drug claim—plaintiff took Solodyn, a prescription acne medication made by defendant Medicis Pharmaceutical Corporation, experienced liver failure while on the medication, and sued. [read post]
3 Jan 2013, 12:54 pm
Tigert involved a fairly straightforward drug claim—plaintiff took Solodyn, a prescription acne medication made by defendant Medicis Pharmaceutical Corporation, experienced liver failure while on the medication, and sued. [read post]
23 Aug 2008, 1:23 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: DRM for streaming music dies a quiet death: (Electronic Frontier Foundation), (Techdirt) CAFC decides Apotex and Impax infringed AstraZeneca’s Prilosec patents: (Law360), (Patent Prospector), (Patent Docs), (GenericsWeb), CAFC upholds lower court’s decision finding USPTO was within its rights to subject a Cooper patent to… [read post]
6 Jun 2008, 6:49 am
: (Spicy IP) Events 9-12 June: (US) Strategies for management of IP – Chicago: (IPR-Helpdesk), 11 June: US PLI ‘Advanced patent licensing 2008: What you need to know before licensing your patent’ – San Francisco: (Patent Docs), 11 June: MARQUES ‘First meeting with Spanish Judges of the Community Trade Mark Courts’ – Alicante: (Class 46), 13-14 June: Centre for European Economic Research conference on ‘The… [read post]
29 Aug 2008, 1:25 pm
: (IP finance), Facebook removes international access to Scrabulous, except from India: (Ars Technica), (Techdirt), Reverse engineering can resolve conflict between standardisation and competition: (Techdirt), Benefits of piracy aren’t always in the expected places: (Techdirt) Events 1-3 September: Federation of Indian Chambers of Commerce and Industry, Department of Industrial Property and Promotion, and WIPO conference on ‘Development and IP: Building synergies… [read post]
